Do early HER2-overexpression breast cancer patients benefit from undergoing neoadjuvant trastuzumab and mastectomy? A meta-analysis

Figures & data

Figure 1 The study selection procedure.

Abbreviation: HER2, human epidermal growth factor receptor 2.

Table 1 The details of eligible articles

First author	Publication year	Study duration	Original nation	Median age, y^a	Median follow-up	Trastuzumab	No. of patients	CT strategy	Radiotherapy
									Study gr.	Control gr.
Mastectomy vs BCT
Herrero-Vicent^Citation1	2016	1998–2014	Spain	49; 50	72 ms	Received	48	NAT	Both
Ihemelandu^Citation2	2008	1998–2005	USA	NA	NA	Absent	43	AT	No	Yes
Gabos^Citation3	2010	1998–2003	Canada	NA	4.8 ys	Absent	88	AT	Both
Debled^Citation4	2015	2005–2012	France	49; 51	46.5 ms	Received	152	NAT	Both
Straver^Citation5	2010	2000–2007	The Netherlands	45	35 ms	Received	56	NAT + AT	Both
Voduc^Citation6	2010	1986–2004	Canada	59	12 ys	Absent	227	AT	Both
Tanioka^Citation7	2010	1996–2006	Japan	54.5	46 ms	Received	44	NAT	Both
Peterson^Citation8	2014	2003–2009	Canada	NA	4.4 ys	Received	748	AT	No	Yes
NAT vs AT
Chatterjee^Citation9	2016	2011–2013	India	53	23.5 ms	Received	75	NAT + AT	Both
Gonzalez-Angulo^Citation10	2015	2001–2012	USA	NA	45 ms	Received	589	NAT + AT	Both
Yang^Citation11	2018	2000–2008	China	NA	6.5 ys^b	Received	60	NAT + AT	Both
Palmieri^Citation12	2015	2006–2011	UK	50.4	53.7 ms	Received	236	NAT + AT	Both

Notes: ^aThe value before the semicolon belongs to the study cohort; the value after it belongs to the control cohort. ^bMean value of follow-up.

Abbreviations: CT, chemotherapy; BCT, breast-conserving therapy; NAT, neoadjuvant therapy; AT, adjuvant therapy; ys, years; ms, months; gr., group; NA, not assessed in publication.

Figure 2 The comparison of overall survival between neoadjuvant trastuzumab and adjuvant trastuzumab.

Abbreviations: NAT, neoadjuvant trastuzumab; AT, adjuvant trastuzumab.

Figure 3 The comparison of local-regional relapse between mastectomy and BCT. (A) Whole group analysis; (B) Subgroup analysis.

Abbreviation: BCT, breast-conserving therapy.

Figure 4 The assessment of risk of bias by the new Cochrane tool. (A) The risk of bias summary; (B) The risk of bias graph.

Figure S1 The Begg’s funnel plot with a 95% confidence interval was created to assess the presence of publication bias OS of neoadjuvant therapy versus adjuvant therapy. p=0.844 according to the Egg’s test.

Figure S2 The Begg’s funnel plot with a 95% confidence interval was created to assess the presence of publication bias in LRR of mastectomy versus breast-conserving therapy. p=0.515 according to the Egg’s test.

Herrero-Vicent C, Guerrero-Zotano A, Gavila-Gregori J, et al.A prognostic index for locoregional recurrence after neoadjuvant chemotherapy. Ecancermedicalscience. 2016;10:647.27433280

 PubMedGoogle Scholar

Ihemelandu CU, Naab TJ, Mezghebe HM, et al. Treatment and survival outcome for molecular breast cancer subtypes in black women. Ann Surg. 2008;247(3):463–469.18376191

 PubMed Web of Science ®Google Scholar

Gabos Z, Thoms J, Ghosh S, et al. The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer. Breast Cancer Res Treat. 2010;124(1):187–194.20814819

 PubMed Web of Science ®Google Scholar

Debled M, MacGrogan G, Breton-Callu C, et al. Surgery following neoadjuvant chemotherapy for HER2-positive locally advanced breast cancer. Time to reconsider the standard attitude. Eur J Cancer. 2015;51(6):697–704.25704790

 PubMed Web of Science ®Google Scholar

Straver ME, Rutgers EJT, Rodenhuis S, et al. The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Ann Surg Oncol. 2010;17(9):2411–2418.20373039

 PubMed Web of Science ®Google Scholar

Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010;28(10):1684–1691.20194857

 PubMed Web of Science ®Google Scholar

Tanioka M, Shimizu C, Yonemori K, et al. Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy. Br J Cancer. 2010;103(3):297–302.20606681

 PubMed Web of Science ®Google Scholar

Peterson DJ, Truong PT, Sadek BT, et al. Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer. Ann Surg Oncol. 2014;21(11):3490–3496.24841346

 PubMed Web of Science ®Google Scholar

Chatterjee S, Arunsingh M, Agrawal S, et al. Outcomes following a moderately hypofractionated adjuvant radiation (START B Type) schedule for breast cancer in an unscreened non-caucasian population. Clin Oncol. 2016;28(10):e165–e172.

 Web of Science ®Google Scholar

Gonzalez-Angulo AM, Parinyanitikul N, Lei X, et al Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy. Br J Cancer. 2015;112(4):630–635.25584488

 PubMed Web of Science ®Google Scholar

Yang H, Zhou L, Wang S, et al. Retrospective analysis of concurrent docetaxel and epirubicin neoadjuvant versus adjuvant chemotherapy: Which leads to better outcomes for different subtype breast cancer patients? Medicine. 2018;97(40):e12690.30290661

 PubMed Web of Science ®Google Scholar

Palmieri C, Macpherson IR, Yan K, et al. Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer. Oncotarget. 2016;7(11):13209–13220.26334099

 PubMedGoogle Scholar